Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6ATAC9P is a **pseudogene** belonging to the small nuclear RNA (snRNA) gene family, specifically derived from the U6atac snRNA involved in the minor spliceosome. Unlike its functional parent U6atac snRNA, which catalyzes minor intron splicing and plays a role in regulating gene expression and cellular stress responses[3], RNU6ATAC9P does not encode a functional transcript or participate directly in splicing or other cellular processes. Pseudogenes like RNU6ATAC9P are generally considered genomic remnants formed by retrotransposition or duplication events and do not possess biological activity or serve as therapeutic targets. The classification as a pseudogene indicates loss of function; as such, it is not a valid target for drug discovery or clinical intervention[1][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6atac small nuclear 9, pseudogene (RNU6ATAC9P).